ADOPT data not major setback for Eliquis from BMS/Pfizer
This article was originally published in Scrip
Eliquis (apixaban), Bristol-Myers Squibb/Pfizer's new oral direct Factor Xa inhibitor anticoagulant, has failed to show superiority to the standard of care low molecular weight heparin enoxaparin (Sanofi's Lovenox/Clexane) in preventing venous thromboembolism in a Phase III trial in patients with acute medical illness.
You may also be interested in...
Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.